<i>In vivo</i> measurement of 5‐aminolaevulinic acid‐induced protoporphyrin IX photobleaching: a comparison of red and blue light of various intensities

Nadeau, Valerie; O'Dwyer, Martin J.; Hamdan, Khaled; Tait, Iain S.; Padgett, Miles J.

doi:10.1111/j.1600-0781.2004.00100.x

Cited by 34 publications

(34 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cells used in this experiment were no more than 10 passages from the original stock in liquid nitrogen. The s.c. and orthotopic MatLyLu rat prostate cancer models were reproduced as previously described (9). Tumors were used for experiments when reaching a size of 6 to 10 mm in diameter.…”

Section: Methodsmentioning

confidence: 99%

“…Light treatment typically starts at 5 to 15 minutes after administration of verteporfin to selectively target blood vessels. This vascular targeting regimen is currently used for AMD treatment in clinic (4) and experimentally for tumor destruction (5,6,8,9).…”

Section: Key Research Accomplishmentsmentioning

confidence: 99%

“…Therefore, red and far red light is generally used for treating bulk tissues. In certain circumstances, when a superficial treatment is highly desirable, such as in the skin, esophagus, or bladder, research has been undertaken to compare blue light excitation to red light excitation, 9 and it is largely true that the depth of damage can be constrained by the use of blue light, whereas infrared lightactivated molecules allow the maximum depth of treatment in PDT.…”

Section: Lightmentioning

confidence: 99%

See 2 more Smart Citations

Enhancing Tumor Drug Delivery by Laser-Activated Vascular Barrier Disruption

Chen¹,

He²

2006

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. REPORT DATE PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERUniversity of the Sciences in Philadelphia Philadelphia, PA 19104 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTESOriginal contains colored plates: ALL DTIC reproductions will be in black and white.14. ABSTRACT An obstacle for successful drug therapy for cancer is the existence of drug delivery barriers, which causes insufficient drug delivery to the tumor tissue. Because of inadequate drug delivery to the tumor tissue, the drug dose has to be increased, which leads to normal tissue toxicity. This delivery problem not only limits the clinical application of existing chemotherapeutics, but also decreases the effectiveness of many new drugs under development for prostate cancer. We found that vascular targeting photodynamic therapy (PDT), a modality involving the combination of a photosensitizer and laser light, is able to disrupt tumor vascular barrier, a significant hindrance to drug delivery. Therefore, tumor accumulation of circulating molecules is significantly enhanced, as demonstrated by intravital fluorescence microscopy and whole-body fluorescence imaging techniques. Immunofluorescence staining of endothelial cytoskeleton structure further indicates microtubule depolymerization, stress actin fiber formation and intercellular gap formation. Based on these results, we propose to use this laser-based therapy to enhance anticancer drug effectiveness. PDT is currently in worldwide multicenter clinical trials for the localized prostate cancer therapy. The available results indicate that PDT employing advanced laser fiber technology and sophisticated light dosimetry is able to treat localized prostate cancer in an effective and safe way. The combination of photosensitization with current chemotherapy or other new drug therapies will greatly improve clinical...

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Key Research Accomplishmentsmentioning

confidence: 99%

Section: Lightmentioning

confidence: 99%

See 1 more Smart Citation

Enhancing Tumor Drug Delivery by Laser-Activated Vascular Barrier Disruption

Chen¹,

He²

2006

View full text Add to dashboard Cite

show abstract

“…光动力疗法(Photodynamic Therapy, PDT)，又称光辐照疗法(Photoradiation Therapy, PRT)或光化学疗法 (Photochemotherapy) [1,2] ，是利用光敏剂分子接受特定波长的光能后通过光化学反应和能量传递将光能转化为分子内能 [3][4][5] ，在有氧条件下，产生多种活性氧物质 (reactive oxygen species, ROS)，包括单线态氧、氧自由基、羟自由基、超氧阴离子等，具有细胞毒作用 [5][6][7] , 它们可进一步与细胞内成分发生光敏化反应，从而对蛋白质、核酸和脂类等生物大分子产生破坏作用，使细胞的结构和功能受到严重影响，导致细胞凋亡或死亡，起到治疗作用 [8,9] ，同时光敏剂自身也会发生光敏化自敏化反应 [10][11][12] 。目前相关研究已证实基于 PDT 过程中的光敏剂光敏反应生成的活性氧是细胞杀伤的主要媒介。光敏剂的光漂白也是由活性氧物质所引起的 [13][14][15] 。因此，对 PDT 过程中活性氧的检测对于 PDT 原理的研究以及光漂白现象的理解有着重要的意义 [16,17] …”

Section: 引言unclassified

Untitled

李¹

2011

View full text Add to dashboard Cite

Abstract:With the development of the basic research of photodynamic therapy (PDT) and a wide range of potential clinical applications have be carried out. The monitoring of reactive oxygen species (ROS) which produced in PDT has become a hot issue of PDT research in recent years. In the paper, the status of ROS in HL60 cells were investigated by fluorescence spectra acquired during PDT. The results showed that the largest number of ROS in PDT was achieved at the optimized conditions(the cells incubation time is 4 hours, the added concentration of ALA is 10 mM/L), in which up to 93.2% PDT efficiency for the HL60 Cells can be obtained within 60 minutes.

show abstract

“…Upon activation, the photosensitizer forms an excited triplet state (via a singlet) which reacts with molecular oxygen and other substrates to produce reactive oxygen species (ROS) that cause the death of tumour cells (1,5,6). While effective, the PDT with porphyrins has several drawbacks, such as long-term skin photosensitivity and loss of absorbance during irradiation due to rapid photobleaching for the prolonged photosensitization entailed (2,7,8). In particular, melanotic melanomas have a poor response to PDT and the reason for this is that melanin absorbs the light at the same wavelength region (400-750 nm) of porphyrins absorption, thus lowering their effect (9,10).…”

Section: Introductionmentioning

confidence: 99%

Apoptosis and cell growth arrest in A375 human melanoma cells by diorganotin(IV) and triorganotin(IV) complexes of [meso-Tetra(4-sulfonatophenyl)porphine] manganese(III)chloride

Costa

Zito

Emma³

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

Abstract.In previous studies we have demonstrated that two derivatives of meso-Tetra(4-sulfonatophenyl)porphine (TPPS), (Bu 2 Sn) 2 TPPS and (Bu 3 Sn) 4 TPPS, cause apoptotic death of A375 melanoma cells and, at lower concentrations, arrest of cell proliferation. In the present study, we examined if the manganese metal inside the porphyrin cavity could improve the efficacy of this class of compounds. Thus, [mesoTetra(4-sulfonatophenyl)porphine]Mn(III)Cl (=MnTPPS) derivatives, namely (Me 2 Sn) 2 MnTPPS, (Bu 2 Sn) 2 MnTPPS, (Me 3 Sn) 4 MnTPPS and (Bu 3 Sn) 4 MnTPPS, were tested on the A375 human melanoma cell line. A cytotoxicity assay showed that (Bu 2 Sn) 2 MnTPPS and (Bu 3 Sn) 4 MnTPPS were highly cytotoxic by inducing apoptosis in melanoma cells, as shown by DNA fragmentation analysis and by apoptotic nuclei fluorescence, and when used at lower concentrations, they affected only cellular proliferation. An arrest of cell proliferation was also observed with (Me 3 Sn) 4 MnTPPS, but at the highest concentrations used. Moreover, the lower concentration of (Bu 3 Sn) 4 MnTPPS induced a change in cell morphology, from a polygonal to an elongated and spindleshaped phenotype, likewise to its cognate (Bu 3 Sn) 4 TPPS, previously tested. Western blotting analysis showed indeed that both tributyltin compounds, i.e. (Bu 3 Sn) 4 MnTPPS and (Bu 3 Sn) 4 TPPS, lowered levels of the major proteins involved in tumorigenesis: ß-catenin, c-myc and snail. We also demonstrated that all compounds entered the cells and localized in the nuclei. In conclusion, our results show that, in spite of the Mn(III) metal introduction, the butyl derivatives always have a higher efficacy than methyl derivatives, and the tributyltin compounds in particular have an interesting effect in vitro on A375 cell proliferation.

show abstract

In vivo measurement of 5‐aminolaevulinic acid‐induced protoporphyrin IX photobleaching: a comparison of red and blue light of various intensities

Cited by 34 publications

References 28 publications

Enhancing Tumor Drug Delivery by Laser-Activated Vascular Barrier Disruption

Enhancing Tumor Drug Delivery by Laser-Activated Vascular Barrier Disruption

Untitled

Apoptosis and cell growth arrest in A375 human melanoma cells by diorganotin(IV) and triorganotin(IV) complexes of [meso-Tetra(4-sulfonatophenyl)porphine] manganese(III)chloride

Contact Info

Product

Resources

About